glp-1/gip vs glp-1 Biology of Incretins: and GIP GLP-1 Receptor Agonists – Peripheral

Probably equal

10 Engineering for a Longer Life Twice-daily injection was never going to be a mass-market product

All five medications share common allegations that their manufacturers knew or should have known about the risks of gastroparesis, intestinal obstruction, and other severe gastrointestinal injuries, yet failed to provide adequate warnings to patients and physicians

doi: 10.1007/s40264-023-01392-3 [DOI] [PMC free article] [PubMed] [Google Scholar] 125.Iber H, Li-Masters T, Chen Q, Yu S, Morgan ET

This industry knows how to evolve and get the balance right, he said

Excessive electrolyte supplementation carries real risks